Sunlenca Product Label
Interaction Color Code
Clinical Bottom Line
Do not coadminister: reduced levels of lenacapavir
Drug 1
Drug 2
Mechanism
Induction of CYP3A by phenobarbital
Clinical Effects
Potential loss of antiviral efficacy
Management
Use alternative agents
Info Source
